癌症合并急性静脉血栓栓塞患者的性别差异。
Gender differences in cancer patients with acute venous thromboembolism.
机构信息
Department of Internal Medicine, Hospital General Universitario Santa Lucía, Murcia, Spain.
Department of Pneumonology, Complejo Hospitalario San Pedro, La Rioja, Spain.
出版信息
Thromb Res. 2015 Feb;135 Suppl 1:S12-5. doi: 10.1016/S0049-3848(15)50433-7. Epub 2015 Feb 9.
BACKGROUND
The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender.
METHODS
We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the course of anticoagulation, according to gender.
RESULTS
As of August 2014, 11,055 patients with active cancer were enrolled in RIETE, of whom 5,104 (46%) were women. During the course of anticoagulation (mean: 142 days), 505 patients developed recurrent VTE, 429 bled and 2730 died. Compared with men, women had a significantly lower rate of fatal bleeding (risk ratio [RR]: 0.69; 95% CI: 0.47-0.99) and death (RR: 0.90; 95% CI: 0.83-0.97), and a non-significantly lower rate of PE recurrences (RR 0.83; 95% CI: 0.65-1.06) and major bleeding (RR: 0.89; 95% CI: 0.74-1.08).
CONCLUSIONS
During the course of anticoagulation, cancer women with VTE had a better outcome than men.
背景
癌症合并急性静脉血栓栓塞症（VTE）患者的结局可能因性别而异。
方法
我们使用 RIETE 数据库，根据性别比较了抗凝过程中 VTE（肺栓塞[PE]或深静脉血栓形成[DVT]）复发、大出血和死亡率的发生率。
结果
截至 2014 年 8 月，RIETE 共纳入 11055 例活动性癌症患者，其中 5104 例（46%）为女性。在抗凝过程中（平均 142 天），505 例患者发生复发性 VTE，429 例患者发生大出血，2730 例患者死亡。与男性相比，女性致命性出血的发生率显著降低（风险比[RR]：0.69；95%置信区间：0.47-0.99）和死亡率（RR：0.90；95%置信区间：0.83-0.97），PE 复发和大出血的发生率非显著降低（RR 0.83；95%置信区间：0.65-1.06 和 RR：0.89；95%置信区间：0.74-1.08）。
结论
在抗凝过程中，癌症合并 VTE 的女性比男性有更好的结局。
Zotero 插件